# Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

> **NCT01951586** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 226 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Denosumab
- **DRUG:** Zoledronic acid
- **DRUG:** Placebo to Denosumab
- **DRUG:** Standard Chemotherapy
- **DRUG:** Placebo to Zoledronic Acid

## Key facts

- **NCT ID:** NCT01951586
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-31
- **Primary completion:** 2016-07-29
- **Final completion:** 2017-11-28
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2021-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01951586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01951586, "Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01951586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*